STX209 · program

Arbaclofen for Multiple sclerosis

Phase 3UnknownRVL Pharmaceuticals, Inc.
  • FDA Orphan Drug Designation (Alleviation Of Signs And Symptoms Of Spasticity Resulting From Multiple Sclerosis), Per Osmotica/RVL 10-K Filings; Grant Date Not Disclosed

Indications for STX209: Autism spectrum disorder · Phase 2 Multiple sclerosis · Phase 3 Fragile X syndrome · Phase 3

Arbaclofen extended-release tablets (Osmotica's Osmodex osmotic tablet, OS440) for spasticity in multiple sclerosis. This is a neurology program, not the lead, recorded for completeness. The first Phase 3 (OS440-3002, NCT01743651; arbaclofen 40 mg/day vs baclofen 80 mg/day vs placebo) was completed in 2014. According to Osmotica, an FDA audit then judged that trial's data insufficient to support a marketing application. The second Phase 3 (OS440-3004, NCT03290131; 536 patients, 40 or 80 mg/day for 12 weeks) significantly reduced TNmAS-MAL spasticity at 40 mg/day vs placebo (LS mean difference -0.39) but missed the co-primary CGIC endpoint. The NDA, first filed in 2015, was resubmitted in June 2020 with a 2020-12-29 goal date. FDA issued a Complete Response Letter on 2020-12-28: it found the statistical analysis of the 40 mg TNmAS-MAL co-primary endpoint inadequately justified and recommended a new study. A Type A meeting followed (2021-03-04), and a Special Protocol Assessment for a further trial was not agreed (FDA letter 2021-10-15). A new Phase 3 (OS440-3006, NCT05179577; 80 mg/day BID, 442 planned) is registered as not yet recruiting, with a January 2027 start. In its FY2022 10-K, RVL Pharmaceuticals said it was looking to sell or out-license arbaclofen ER. No later owner or development decision could be cited, so status is unknown.

Development timeline

Phase 3Nov 2012 – Jan 2028
  1. UpcomingClinicalTrials.gov estimated primary completion of Phase 3 OS440-3006 (NCT05179577), arbaclofen ER 80 mg/day vs placebo in MS spasticity: January 2028. The study is not yet recruiting, with an estimated January 2027 start.
  2. RVL Pharmaceuticals' FY2022 10-K says it is looking to sell or out-license arbaclofen ER tablets. No later disclosure of the program's owner or status was found.↗
  3. FDA regulatory meeting / outcomeFDA declines to agree a Special Protocol Assessment for a new arbaclofen ER study↗
  4. FDA regulatory meeting / outcomeType A meeting with FDA on the arbaclofen ER CRL↗
  5. FDA Complete Response Letter, which recommends a new study to provide substantial evidence of efficacy. The program reverts to a Phase 3 requirement.↗
  6. Complete Response LetterFDA issues a Complete Response Letter for arbaclofen ER in MS spasticity↗
  7. Phase 3 OS440-3002 (NCT01743651) of arbaclofen tablets 40 mg/day vs baclofen and placebo in MS spasticity starts.
Filed (NDA)Jun 2020 – Jul 2020
  1. PDUFA date setFDA sets a 2020-12-29 goal date for the arbaclofen ER NDA↗
  2. Osmotica resubmits the arbaclofen ER NDA (first submitted in 2015) for spasticity in multiple sclerosis. FDA accepts it as a complete response to its 2016-07-09 action letter and sets a 2020-12-29 goal date.↗
  3. NDA/BLA filedOsmotica resubmits the arbaclofen ER NDA for MS spasticity↗

Readouts

  • January 2028AnticipatedRegistry resultsNCT05179577

    ClinicalTrials.gov estimated primary completion of Phase 3 OS440-3006 (NCT05179577), arbaclofen ER 80 mg/day vs placebo in MS spasticity: January 2028. The study is not yet recruiting, with an estimated January 2027 start.

Clinical trials in Multiple sclerosis

NCT05179577OS440-3006Phase 3Activen=442

A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006)

Started Jan 2027· Primary completion Jan 2028

NCT03319732OS440-3005Phase 3Completedn=323

An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)

Started Apr 2018· Primary completion Jan 2020· 📍 1 site across 1 country (United States)

NCT03290131OS440-3004Phase 3Completedn=536

A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis

Started Jan 2018· Primary completion Dec 2018· 📍 30 sites across 7 countries (Poland, Bulgaria, Belarus, Croatia)

NCT01743651OS440-3002Phase 3Completedn=353

A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis

Started Nov 2012· Primary completion Apr 2014· 📍 48 sites across 3 countries (United States, Ukraine, Russia)

Formulations

FormulationRouteRegimenPharmacokinetics
Arbaclofen extended-release tablets (Osmodex), 40 or 80 mg/day BIDOsmodex osmotic extended-release tablet
Arbaclofen ER 40 mg/day or 80 mg/day in two daily doses (12-hour dosing interval) in the Phase 3 OS440-3004 study (NCT03290131). The planned OS440-3006 study (NCT05179577) uses 80 mg/day, twice daily.
OralTwice daily—

Mechanism of action (compound-wide)

Selective orthosteric agonist of the GABA-B receptor, a Gi/o-coupled class C GPCR that works as a GABAB1/GABAB2 heterodimer; the agonist binds the GABAB1 subunit. Arbaclofen is the active R-enantiomer of baclofen, with 100- to 1000-fold greater GABA-B specificity than the S-enantiomer and about 5-fold greater potency than racemic baclofen. In the neurodevelopmental programs, the hypothesis is that GABA-B activation rebalances cortical excitation and inhibition and dampens excess glutamate release, which is implicated in fragile X syndrome (Fmr1 knockout models) and some autism. In spasticity, the effect comes from presynaptic inhibition of spinal reflexes, as with baclofen.

TargetActionAffinity
GABA-B receptorprimaryGABBR1Agonist—ⓘ

← Full STX209 compound page (identity, identifiers, all indications)

Sources

  1. NCT01743651 (OS440-3002) — Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis — ClinicalTrials.gov (U.S. National Library of Medicine)
  2. NCT03290131 (OS440-3004) — A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS — ClinicalTrials.gov (U.S. National Library of Medicine)
  3. NCT03319732 (OS440-3005) — A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS — ClinicalTrials.gov (U.S. National Library of Medicine)
  4. NCT05179577 (OS440-3006) — A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis — ClinicalTrials.gov (U.S. National Library of Medicine)
  5. Okuda DT, et al. Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial. Brain Commun 2022;4(6):fcac300 — Brain Communications (OUP) / PubMed
  6. Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. FDA for Arbaclofen Extended Release Tablets (8-K Ex. 99.1, 2020-12-29) — Osmotica Pharmaceuticals plc / SEC EDGAR
  7. RVL Pharmaceuticals plc Form 10-K for fiscal year 2021 (filed 2022-03-30) — RVL Pharmaceuticals plc / SEC EDGAR
  8. RVL Pharmaceuticals plc Form 10-K for fiscal year 2022 (filed 2023-03-20) — RVL Pharmaceuticals plc / SEC EDGAR